Growth Hormone Deficiency Is Associated with Decreased Quality of Life in Patients with Prior Acromegaly
Autor: | Brooke Swearingen, Andrea L. Utz, Lisa B. Nachtigall, Tamara Wexler, Karen Kuhlthau, Catherine Beauregard, Karen K. Miller, Gwenda J. Graham, Zehra B. Omer, Beverly M. K. Biller, Anne Klibanski, Lindsay Gunnell, Jay S. Loeffler |
---|---|
Rok vydání: | 2009 |
Předmět: |
Adult
Male medicine.medical_specialty Cross-sectional study Endocrinology Diabetes and Metabolism Emotions Clinical Biochemistry Context (language use) Biochemistry Growth hormone deficiency Endocrinology Quality of life Surveys and Questionnaires Internal medicine Acromegaly medicine Humans Insulin-Like Growth Factor I Growth Disorders Depression (differential diagnoses) Human Growth Hormone business.industry Mental Disorders Biochemistry (medical) Middle Aged medicine.disease Cross-Sectional Studies Clinical research Quality of Life Anxiety Original Article Female medicine.symptom business |
Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 94:2471-2477 |
ISSN: | 1945-7197 0021-972X |
DOI: | 10.1210/jc.2008-2671 |
Popis: | Context: Both GH deficiency (GHD) and GH excess are associated with a decreased quality of life. However, it is unknown whether patients with GHD after treatment for acromegaly have a poorer quality of life than those with normal GH levels after cure of acromegaly. Objective: The aim of the study was to determine whether patients with GHD and prior acromegaly have a poorer quality of life than those with GH sufficiency after cure of acromegaly. Design and Setting: We conducted a cross-sectional study in a General Clinical Research Center. Study Participants: Forty-five patients with prior acromegaly participated: 26 with GHD and 19 with GH sufficiency. Intervention: There were no interventions. Main Outcome Measures: We evaluated quality of life, as measured by 1) the Quality of Life Adult Growth Hormone Deficiency Assessment (QoL-AGHDA); 2) the Short-Form Health Survey (SF-36); and 3) the Symptom Questionnaire. Results: Mean scores on all subscales of all questionnaires, except for the anger/hostility and anxiety subscales of the Symptom Questionnaire, showed significantly impaired quality of life in the GH-deficient group compared with the GH-sufficient group. Peak GH levels after GHRH-arginine stimulation levels were inversely associated with QoL-AGHDA scale scores (R = −0.53; P = 0.0005) and the Symptom Questionnaire Depression subscale scores (R = −0.35; P = 0.031) and positively associated with most SF-36 subscale scores. Conclusions: Our data are the first to demonstrate a reduced quality of life in patients who develop GHD after cure of acromegaly compared to those who are GH sufficient. Further studies are warranted to determine whether GH replacement would improve quality of life for patients with GHD after cure from acromegaly. |
Databáze: | OpenAIRE |
Externí odkaz: |